Zhengye Biotechnology (NASDAQ:ZYBT) Trading 2.8% Higher – Time to Buy?

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) shares traded up 2.8% on Thursday . The company traded as high as $1.84 and last traded at $1.84. 17,284 shares traded hands during mid-day trading, a decline of 32% from the average session volume of 25,481 shares. The stock had previously closed at $1.79.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Zhengye Biotechnology in a report on Tuesday, October 14th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Zhengye Biotechnology Price Performance

The firm has a fifty day moving average of $2.25 and a 200-day moving average of $5.14.

Hedge Funds Weigh In On Zhengye Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of ZYBT. Citadel Advisors LLC purchased a new position in Zhengye Biotechnology in the 3rd quarter worth approximately $31,000. Millennium Management LLC acquired a new position in shares of Zhengye Biotechnology in the 3rd quarter valued at approximately $38,000. WINTON GROUP Ltd purchased a new position in shares of Zhengye Biotechnology during the 3rd quarter valued at approximately $56,000. Geode Capital Management LLC acquired a new stake in shares of Zhengye Biotechnology during the second quarter worth approximately $174,000. Finally, Invesco Ltd. bought a new stake in shares of Zhengye Biotechnology in the second quarter worth $220,000.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.